Synthesis and validation of [F-18]mBPET-1, a fluorine-18 labelled mTOR inhibitor derivative based on a benzofuran backbone
Christian W Wichmann, Yit Wooi Goh, Adam C Parslow, Angela Rigopoulos, Nancy Guo, Andrew M Scott, Uwe Ackermann, Jonathan M White
EJNMMI RADIOPHARMACY AND CHEMISTRY | SPRINGERNATURE | Published : 2020
BACKGROUND: Targeted therapy of HER2 positive breast cancer has led to clinical success in some cases with primary and secondary resistance being major obstacles. Due to the substantial involvement of mTOR kinase in cell growth and proliferation pathways it is now targeted in combination treatments to counteract HER2 targeted therapy resistance. However, the selection of receptive patient populations for a specific drug combination is crucial. This work aims to develop a molecular probe capable of identifying patients with tumour populations which are receptive to RAD001 combination therapy. Based on the structure of a mTOR inhibitor specific for mTORC1, we designed, synthesised and characte..View full abstract
Awarded by NHMRC
This word was funded by NHMRC grants 1092788 and 1084178. Further partial support was provided by a La Trobe University Understanding Disease Research Focus Area -Mini Start-Up Project grant.